Jiang Ruming, Dai Jun, Dong Xiaoqi, Wang Quan, Meng Zijuan, Guo Jingjing, Yu Yongjiang, Wang Shixuan, Xia Fan, Zhao Zujin, Lou Xiaoding, Tang Ben Zhong
State Key Laboratory of Luminescent Materials and Devices, Guangdong Provincial Key Laboratory of Luminescence from Molecular Aggregates, SCUT-HKUST Joint Research Institute, South China University of Technology, Guangzhou, 510640, China.
Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430074, China.
Adv Mater. 2021 Jun;33(22):e2101158. doi: 10.1002/adma.202101158. Epub 2021 Apr 26.
Multimodal therapy is attracting increasing attention to improve tumor treatment efficacy, but generally requires various complicated ingredients combined within one theranostic system to achieve multiple functions. Herein, a multifunctional theranostic nanoplatform based on a single aggregation-induced-emission luminogen (AIEgen), DDTB, is designed to integrate near-infrared (NIR) fluorescence, photothermal, photodynamic, and immunological effects. Intravenously injected AIEgen-based nanoparticles can efficiently accumulate in tumors with NIR fluorescence to provide preoperative diagnosis. Most of the tumors are excised under intraoperative fluorescence navigation, whereafter, some microscopic residual tumors are completely ablated by photodynamic and photothermal therapies for maximally killing the tumor cells and tissues. Up to 90% of the survival rate can be achieved by this synergistic image-guided surgery and photodynamic and photothermal therapies. Importantly, the nanoparticles-mediated photothermal/photodynamic therapy plus programmed death-ligand 1 antibody significantly induce tumor elimination by enhancing the effect of immunotherapy. This theranostic strategy on the basis of a single AIEgen significantly improves the survival of cancer mice with maximized therapeutic outcomes, and holds great promise for clinical cancer treatment.
多模态疗法在提高肿瘤治疗效果方面正受到越来越多的关注,但通常需要在一个诊疗系统中组合各种复杂成分以实现多种功能。在此,设计了一种基于单一聚集诱导发光分子(AIEgen)DDTB的多功能诊疗纳米平台,以整合近红外(NIR)荧光、光热、光动力和免疫效应。静脉注射基于AIEgen的纳米颗粒能够凭借NIR荧光在肿瘤中高效蓄积,以提供术前诊断。大多数肿瘤在术中荧光导航下被切除,之后,一些微小残留肿瘤通过光动力和光热疗法被完全消融,从而最大程度地杀死肿瘤细胞和组织。通过这种协同的图像引导手术以及光动力和光热疗法,可实现高达90%的生存率。重要的是,纳米颗粒介导的光热/光动力疗法加上程序性死亡配体1抗体,通过增强免疫治疗效果显著诱导肿瘤消除。这种基于单一AIEgen的诊疗策略显著提高了癌症小鼠的生存率,实现了最大化的治疗效果,对临床癌症治疗具有巨大的前景。